SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

• Published in: Inflammatory bowel diseases Vol. 27; no. Supplement_1; p. S1
• Main Authors: Hanauer, Stephen, O’Reilly, Terry, Lester, Robert, Slatkin, Neal, Lee, Jimin, Franklin, Howard, Bulawski, Angela, Israel, Robert
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 21.01.2021
• Subjects: Antibiotics; Lymphocytes

Abstract Objective To evaluate the safety profile of amiselimod, a selective sphingosine 1-phosphate receptor modulator which has been shown to regulate lymphocyte trafficking and is in development for the treatment of inflammatory bowel disease. Methods A randomized, double-blind, multiple-dose, pl...